{"columns":[{"name":"Id","type":"int64"},{"name":"IndicatorCode","type":"string"},{"name":"SpatialDimType","type":"string"},{"name":"SpatialDim","type":"string"},{"name":"ParentLocationCode","type":"string"},{"name":"TimeDimType","type":"string"},{"name":"ParentLocation","type":"string"},{"name":"Dim1Type","type":"string"},{"name":"TimeDim","type":"int64"},{"name":"Dim1","type":"string"},{"name":"Dim2Type","type":"string"},{"name":"Dim2","type":"string"},{"name":"Dim3Type","type":"string"},{"name":"Dim3","type":"string"},{"name":"DataSourceDimType","type":"string"},{"name":"DataSourceDim","type":"string"},{"name":"Value","type":"string"},{"name":"NumericValue","type":"double"},{"name":"Low","type":"string"},{"name":"High","type":"string"},{"name":"Comments","type":"string"},{"name":"Date","type":"string"},{"name":"TimeDimensionValue","type":"string"},{"name":"TimeDimensionBegin","type":"string"},{"name":"TimeDimensionEnd","type":"string"}],"n_rows":408,"rows_kept":408,"cut":false,"text_format":"parquet-jsonl-2026-10-02","bounds":{"document_bytes":16777216,"package_text_limit_bytes":33554432,"package_text_slack_bytes":1024,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096,"vector_min":64,"vector_head_fixed":16,"vector_head_variable":64,"kv_value_chars":1048576,"nesting_max":64,"binary_text":true},"cells_cut":0,"cells_bad_utf8":0,"cells_raw":0,"cells_binary":0,"cells_binary_text":0,"cells_vector":0,"n_row_groups":1,"reader":"pyarrow 23.0.1, python 3.13","created_by":"DuckDB","schema":{"fields":[{"name":"Id","type":"int64","nullable":true,"metadata":null,"children":null},{"name":"IndicatorCode","type":"string","nullable":true,"metadata":null,"children":null},{"name":"SpatialDimType","type":"string","nullable":true,"metadata":null,"children":null},{"name":"SpatialDim","type":"string","nullable":true,"metadata":null,"children":null},{"name":"ParentLocationCode","type":"string","nullable":true,"metadata":null,"children":null},{"name":"TimeDimType","type":"string","nullable":true,"metadata":null,"children":null},{"name":"ParentLocation","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Dim1Type","type":"string","nullable":true,"metadata":null,"children":null},{"name":"TimeDim","type":"int64","nullable":true,"metadata":null,"children":null},{"name":"Dim1","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Dim2Type","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Dim2","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Dim3Type","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Dim3","type":"string","nullable":true,"metadata":null,"children":null},{"name":"DataSourceDimType","type":"string","nullable":true,"metadata":null,"children":null},{"name":"DataSourceDim","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Value","type":"string","nullable":true,"metadata":null,"children":null},{"name":"NumericValue","type":"double","nullable":true,"metadata":null,"children":null},{"name":"Low","type":"string","nullable":true,"metadata":null,"children":null},{"name":"High","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Comments","type":"string","nullable":true,"metadata":null,"children":null},{"name":"Date","type":"string","nullable":true,"metadata":null,"children":null},{"name":"TimeDimensionValue","type":"string","nullable":true,"metadata":null,"children":null},{"name":"TimeDimensionBegin","type":"string","nullable":true,"metadata":null,"children":null},{"name":"TimeDimensionEnd","type":"string","nullable":true,"metadata":null,"children":null}],"parquet":"required group field_id=-1 duckdb_schema {\n  optional int64 field_id=-1 Id (Int(bitWidth=64, isSigned=true));\n  optional binary field_id=-1 IndicatorCode (String);\n  optional binary field_id=-1 SpatialDimType (String);\n  optional binary field_id=-1 SpatialDim (String);\n  optional binary field_id=-1 ParentLocationCode (String);\n  optional binary field_id=-1 TimeDimType (String);\n  optional binary field_id=-1 ParentLocation (String);\n  optional binary field_id=-1 Dim1Type (String);\n  optional int64 field_id=-1 TimeDim (Int(bitWidth=64, isSigned=true));\n  optional binary field_id=-1 Dim1 (String);\n  optional binary field_id=-1 Dim2Type (String);\n  optional binary field_id=-1 Dim2 (String);\n  optional binary field_id=-1 Dim3Type (String);\n  optional binary field_id=-1 Dim3 (String);\n  optional binary field_id=-1 DataSourceDimType (String);\n  optional binary field_id=-1 DataSourceDim (String);\n  optional binary field_id=-1 Value (String);\n  optional double field_id=-1 NumericValue;\n  optional binary field_id=-1 Low (String);\n  optional binary field_id=-1 High (String);\n  optional binary field_id=-1 Comments (String);\n  optional binary field_id=-1 Date (String);\n  optional binary field_id=-1 TimeDimensionValue (String);\n  optional binary field_id=-1 TimeDimensionBegin (String);\n  optional binary field_id=-1 TimeDimensionEnd (String);\n}\n"},"kv_metadata":[]}
[6528625,"AMR_INFECT_ECOLI","COUNTRY","QAT","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"40",40.0,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[7073999,"AMR_INFECT_ECOLI","COUNTRY","MUS","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"52.7",52.68,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[761689,"AMR_INFECT_ECOLI","COUNTRY","HRV","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"14.8",14.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3679665,"AMR_INFECT_ECOLI","COUNTRY","MYS","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"24.0",23.97,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7251632,"AMR_INFECT_ECOLI","COUNTRY","MOZ","AFR","YEAR","Africa",null,2019,null,null,null,null,null,null,null,"28",28.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4286514,"AMR_INFECT_ECOLI","UNREGION","150",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"12.5",12.53,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4470105,"AMR_INFECT_ECOLI","COUNTRY","TZA","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"75",75.0,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5370497,"AMR_INFECT_ECOLI","COUNTRY","CZE","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"15.4",15.36,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5377338,"AMR_INFECT_ECOLI","UNREGION","154",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"11.3",11.27,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2009481,"AMR_INFECT_ECOLI","COUNTRY","ZMB","AFR","YEAR","Africa",null,2017,null,null,null,null,null,null,null,"51.5",51.52,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[345958,"AMR_INFECT_ECOLI","UNREGION","145",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"48.5",48.5,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[2424582,"AMR_INFECT_ECOLI","COUNTRY","LBR","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"40",40.0,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4947643,"AMR_INFECT_ECOLI","COUNTRY","LKA","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"63",63.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[18386,"AMR_INFECT_ECOLI","COUNTRY","UGA","AFR","YEAR","Africa",null,2019,null,null,null,null,null,null,null,"60",60.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6494838,"AMR_INFECT_ECOLI","UNREGION","722",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"63",63.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5772837,"AMR_INFECT_ECOLI","UNREGION","432",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"58.4",58.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[775533,"AMR_INFECT_ECOLI","COUNTRY","JPN","WPR","YEAR","Western Pacific",null,2016,null,null,null,null,null,null,null,"18.9",18.94,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[2581289,"AMR_INFECT_ECOLI","COUNTRY","POL","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"18",18.02,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[7265505,"AMR_INFECT_ECOLI","COUNTRY","IRN","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"90",90.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[516584,"AMR_INFECT_ECOLI","COUNTRY","BHR","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"59.1",59.06,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5889083,"AMR_INFECT_ECOLI","COUNTRY","RUS","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"73.1",73.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3120844,"AMR_INFECT_ECOLI","COUNTRY","GBR","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"10.7",10.68,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[625698,"AMR_INFECT_ECOLI","GLOBAL","GLOBAL",null,"YEAR",null,null,2020,null,null,null,null,null,null,null,"41.8",41.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2023-06-09T14:17:55+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3673165,"AMR_INFECT_ECOLI","COUNTRY","KWT","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"51.3",51.28,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6066453,"AMR_INFECT_ECOLI","COUNTRY","COL","AMR","YEAR","Americas",null,2021,null,null,null,null,null,null,null,"30.8",30.77,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6392802,"AMR_INFECT_ECOLI","COUNTRY","FIN","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"6.1",6.14,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[6590473,"AMR_INFECT_ECOLI","COUNTRY","LVA","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"28.2",28.24,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[3707451,"AMR_INFECT_ECOLI","UNREGION","35",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"40.6",40.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3837065,"AMR_INFECT_ECOLI","COUNTRY","GBR","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"10.4",10.44,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3741644,"AMR_INFECT_ECOLI","COUNTRY","DNK","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"6.3",6.31,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[496275,"AMR_INFECT_ECOLI","COUNTRY","TLS","SEAR","YEAR","South-East Asia",null,2021,null,null,null,null,null,null,null,"53.9",53.85,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1715838,"AMR_INFECT_ECOLI","UNREGION","142",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"55.2",55.19,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1982440,"AMR_INFECT_ECOLI","COUNTRY","MLT","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"18.2",18.16,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4879993,"AMR_INFECT_ECOLI","COUNTRY","IND","SEAR","YEAR","South-East Asia",null,2017,null,null,null,null,null,null,null,"75.1",75.11,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[2690846,"AMR_INFECT_ECOLI","COUNTRY","IND","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"86.8",86.81,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2282699,"AMR_INFECT_ECOLI","COUNTRY","IND","SEAR","YEAR","South-East Asia",null,2021,null,null,null,null,null,null,null,"77.6",77.59,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6216898,"AMR_INFECT_ECOLI","COUNTRY","PHL","WPR","YEAR","Western Pacific",null,2017,null,null,null,null,null,null,null,"39.6",39.56,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[32437,"AMR_INFECT_ECOLI","COUNTRY","BHR","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"57.8",57.81,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7054126,"AMR_INFECT_ECOLI","COUNTRY","FRA","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"8.9",8.92,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2173424,"AMR_INFECT_ECOLI","COUNTRY","FRA","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"9.1",9.07,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4388970,"AMR_INFECT_ECOLI","UNREGION","202",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"49.5",49.5,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4566116,"AMR_INFECT_ECOLI","COUNTRY","SAU","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"53.0",52.97,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3107448,"AMR_INFECT_ECOLI","UNREGION","62",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"73.1",73.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5111516,"AMR_INFECT_ECOLI","COUNTRY","DNK","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"7.3",7.27,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6856850,"AMR_INFECT_ECOLI","COUNTRY","PHL","WPR","YEAR","Western Pacific",null,2016,null,null,null,null,null,null,null,"38",38.02,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[4893794,"AMR_INFECT_ECOLI","COUNTRY","MDG","AFR","YEAR","Africa",null,2018,null,null,null,null,null,null,null,"33.3",33.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2486443,"AMR_INFECT_ECOLI","COUNTRY","JOR","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"64.5",64.52,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5957553,"AMR_INFECT_ECOLI","COUNTRY","THA","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"39.4",39.4,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2105354,"AMR_INFECT_ECOLI","COUNTRY","LUX","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"10.7",10.75,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3155317,"AMR_INFECT_ECOLI","COUNTRY","ARG","AMR","YEAR","Americas",null,2017,null,null,null,null,null,null,null,"18.4",18.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[2194046,"AMR_INFECT_ECOLI","UNREGION","753",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"34.9",34.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[803346,"AMR_INFECT_ECOLI","UNREGION","62",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"64.1",64.1,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1355321,"AMR_INFECT_ECOLI","COUNTRY","GEO","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"55.8",55.77,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5527927,"AMR_INFECT_ECOLI","COUNTRY","POL","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"18.8",18.83,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[441927,"AMR_INFECT_ECOLI","COUNTRY","ARG","AMR","YEAR","Americas",null,2020,null,null,null,null,null,null,null,"21.2",21.21,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3107732,"AMR_INFECT_ECOLI","GLOBAL","GLOBAL",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"35.8",35.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-11-04T12:05:21+01:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[2438951,"AMR_INFECT_ECOLI","UNREGION","150",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"18.4",18.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4682511,"AMR_INFECT_ECOLI","COUNTRY","AUS","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"12.5",12.46,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6884559,"AMR_INFECT_ECOLI","COUNTRY","LTU","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"13.3",13.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2085177,"AMR_INFECT_ECOLI","COUNTRY","MDA","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"81.8",81.82,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2957427,"AMR_INFECT_ECOLI","COUNTRY","DEU","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"12.3",12.28,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4962058,"AMR_INFECT_ECOLI","UNREGION","11",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"39.7",39.74,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4785349,"AMR_INFECT_ECOLI","COUNTRY","KHM","WPR","YEAR","Western Pacific",null,2018,null,null,null,null,null,null,null,"72.8",72.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4832675,"AMR_INFECT_ECOLI","UNREGION","35",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"58.8",58.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[544500,"AMR_INFECT_ECOLI","COUNTRY","ARE","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"51.7",51.67,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3776268,"AMR_INFECT_ECOLI","COUNTRY","TUN","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"33.9",33.86,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1103179,"AMR_INFECT_ECOLI","COUNTRY","LBN","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"56.4",56.41,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5152699,"AMR_INFECT_ECOLI","COUNTRY","LVA","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"18.9",18.91,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[5480563,"AMR_INFECT_ECOLI","UNREGION","15",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"35.9",35.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[1123679,"AMR_INFECT_ECOLI","COUNTRY","NOR","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"6.8",6.75,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4819187,"AMR_INFECT_ECOLI","COUNTRY","AUT","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"9.4",9.43,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3148924,"AMR_INFECT_ECOLI","COUNTRY","ITA","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"33.6",33.61,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5282688,"AMR_INFECT_ECOLI","COUNTRY","LVA","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"18.1",18.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[7163984,"AMR_INFECT_ECOLI","COUNTRY","AUS","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"13.4",13.36,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2473475,"AMR_INFECT_ECOLI","UNREGION","747",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"54.8",54.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3271521,"AMR_INFECT_ECOLI","COUNTRY","ZAF","AFR","YEAR","Africa",null,2018,null,null,null,null,null,null,null,"30.4",30.45,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6210771,"AMR_INFECT_ECOLI","COUNTRY","GRC","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"24.5",24.46,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[7177703,"AMR_INFECT_ECOLI","COUNTRY","NLD","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"6.2",6.16,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[7184506,"AMR_INFECT_ECOLI","UNREGION","202",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"65.3",65.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[483422,"AMR_INFECT_ECOLI","UNREGION","513",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"35.3",35.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[3476219,"AMR_INFECT_ECOLI","COUNTRY","PAK","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"86.2",86.21,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[2160542,"AMR_INFECT_ECOLI","UNREGION","15",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"66.7",66.7,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[12733,"AMR_INFECT_ECOLI","COUNTRY","NLD","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"6.6",6.55,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4880859,"AMR_INFECT_ECOLI","COUNTRY","NOR","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"5.1",5.13,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1942311,"AMR_INFECT_ECOLI","COUNTRY","LTU","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"9.7",9.7,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[5773944,"AMR_INFECT_ECOLI","UNREGION","753",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"38",38.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[6040139,"AMR_INFECT_ECOLI","COUNTRY","MDG","AFR","YEAR","Africa",null,2019,null,null,null,null,null,null,null,"40.5",40.54,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5282925,"AMR_INFECT_ECOLI","COUNTRY","ARE","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"48.4",48.43,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5282926,"AMR_INFECT_ECOLI","COUNTRY","BRN","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"17.3",17.3,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3933669,"AMR_INFECT_ECOLI","UNREGION","18",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"30.7",30.74,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6714751,"AMR_INFECT_ECOLI","COUNTRY","BEL","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"8.3",8.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7075459,"AMR_INFECT_ECOLI","COUNTRY","CYP","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"51.6",51.61,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3824459,"AMR_INFECT_ECOLI","COUNTRY","GBR","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"10.3",10.26,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[817762,"AMR_INFECT_ECOLI","COUNTRY","GRC","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"21.7",21.73,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5378697,"AMR_INFECT_ECOLI","COUNTRY","THA","SEAR","YEAR","South-East Asia",null,2016,null,null,null,null,null,null,null,"40.3",40.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[2412695,"AMR_INFECT_ECOLI","UNREGION","145",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"54.2",54.25,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4738024,"AMR_INFECT_ECOLI","COUNTRY","AUT","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"9.1",9.06,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6892054,"AMR_INFECT_ECOLI","COUNTRY","CYP","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"19.6",19.57,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1744225,"AMR_INFECT_ECOLI","UNREGION","514",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"40.5",40.54,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1867271,"AMR_INFECT_ECOLI","UNREGION","155",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"9.7",9.67,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2821349,"AMR_INFECT_ECOLI","COUNTRY","UKR","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"50",50.0,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6496166,"AMR_INFECT_ECOLI","COUNTRY","RUS","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"58.3",58.26,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5221530,"AMR_INFECT_ECOLI","COUNTRY","TTO","AMR","YEAR","Americas",null,2021,null,null,null,null,null,null,null,"27.8",27.78,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4710691,"AMR_INFECT_ECOLI","UNREGION","199",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"50.5",50.5,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1267424,"AMR_INFECT_ECOLI","COUNTRY","QAT","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"48.9",48.92,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6584865,"AMR_INFECT_ECOLI","COUNTRY","ARE","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"48.1",48.07,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3531141,"AMR_INFECT_ECOLI","COUNTRY","BTN","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"53.9",53.93,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4015486,"AMR_INFECT_ECOLI","UNREGION","30",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"38.6",38.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[940848,"AMR_INFECT_ECOLI","UNREGION","199",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"56.8",56.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1281035,"AMR_INFECT_ECOLI","COUNTRY","LBN","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"50.5",50.53,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1342619,"AMR_INFECT_ECOLI","COUNTRY","MYS","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"25.8",25.79,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4635970,"AMR_INFECT_ECOLI","UNREGION","199",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"61.9",61.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[4690351,"AMR_INFECT_ECOLI","COUNTRY","HRV","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"15.6",15.58,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1445065,"AMR_INFECT_ECOLI","COUNTRY","DEU","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"11.5",11.46,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5180820,"AMR_INFECT_ECOLI","COUNTRY","OMN","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"63.9",63.92,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4097529,"AMR_INFECT_ECOLI","UNREGION","135",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"56.6",56.58,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[3510993,"AMR_INFECT_ECOLI","COUNTRY","NGA","AFR","YEAR","Africa",null,2017,null,null,null,null,null,null,null,"77.2",77.19,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[381624,"AMR_INFECT_ECOLI","COUNTRY","CZE","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"14.3",14.31,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4036213,"AMR_INFECT_ECOLI","COUNTRY","IRN","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"70.3",70.25,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1070541,"AMR_INFECT_ECOLI","COUNTRY","MLI","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"46.4",46.38,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1574845,"AMR_INFECT_ECOLI","COUNTRY","UGA","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"80.0",80.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3415697,"AMR_INFECT_ECOLI","COUNTRY","IRL","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"12.9",12.88,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6557946,"AMR_INFECT_ECOLI","COUNTRY","THA","SEAR","YEAR","South-East Asia",null,2017,null,null,null,null,null,null,null,"41.7",41.72,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[1036728,"AMR_INFECT_ECOLI","COUNTRY","ITA","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"24.6",24.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4642940,"AMR_INFECT_ECOLI","COUNTRY","TZA","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"78.0",77.98,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3524751,"AMR_INFECT_ECOLI","COUNTRY","XKX",null,"YEAR",null,null,2020,null,null,null,null,null,null,null,"30",30.0,null,null,"All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:52+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5317741,"AMR_INFECT_ECOLI","COUNTRY","GBR","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"11",10.97,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4342794,"AMR_INFECT_ECOLI","COUNTRY","PHL","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"44.0",44.03,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[177391,"AMR_INFECT_ECOLI","COUNTRY","THA","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"36.4",36.42,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[518307,"AMR_INFECT_ECOLI","COUNTRY","ARG","AMR","YEAR","Americas",null,2019,null,null,null,null,null,null,null,"19",18.98,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[7253614,"AMR_INFECT_ECOLI","COUNTRY","GEO","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"56.6",56.58,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[7308048,"AMR_INFECT_ECOLI","COUNTRY","NOR","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"5.5",5.52,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4206792,"AMR_INFECT_ECOLI","COUNTRY","AUT","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"8.2",8.16,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2938129,"AMR_INFECT_ECOLI","COUNTRY","TUN","EMR","YEAR","Eastern Mediterranean",null,2016,null,null,null,null,null,null,null,"25.5",25.46,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[1588731,"AMR_INFECT_ECOLI","COUNTRY","IND","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"80.8",80.81,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1486163,"AMR_INFECT_ECOLI","COUNTRY","LAO","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"50.8",50.85,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1117921,"AMR_INFECT_ECOLI","COUNTRY","SGP","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"30.5",30.48,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1261183,"AMR_INFECT_ECOLI","COUNTRY","OMN","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"78.9",78.91,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6626449,"AMR_INFECT_ECOLI","UNREGION","753",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"37.3",37.26,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[170645,"AMR_INFECT_ECOLI","COUNTRY","BRN","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"12.6",12.58,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[361708,"AMR_INFECT_ECOLI","UNREGION","34",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"39.9",39.93,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1772293,"AMR_INFECT_ECOLI","COUNTRY","SWE","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"7.6",7.62,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2011582,"AMR_INFECT_ECOLI","COUNTRY","BRA","AMR","YEAR","Americas",null,2019,null,null,null,null,null,null,null,"27.7",27.74,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[654784,"AMR_INFECT_ECOLI","COUNTRY","MKD","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"64.3",64.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2141049,"AMR_INFECT_ECOLI","UNREGION","432",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"18.3",18.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4547431,"AMR_INFECT_ECOLI","COUNTRY","PER","AMR","YEAR","Americas",null,2020,null,null,null,null,null,null,null,"71.7",71.7,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[211848,"AMR_INFECT_ECOLI","COUNTRY","BRN","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"17.2",17.24,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[273179,"AMR_INFECT_ECOLI","COUNTRY","BGD","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"93.1",93.1,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[3907355,"AMR_INFECT_ECOLI","COUNTRY","PAK","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"85.2",85.16,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1602743,"AMR_INFECT_ECOLI","COUNTRY","GHA","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"77.8",77.78,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6578872,"AMR_INFECT_ECOLI","COUNTRY","DEU","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"9.0",8.96,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7172135,"AMR_INFECT_ECOLI","COUNTRY","NOR","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"5.6",5.58,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[3975648,"AMR_INFECT_ECOLI","COUNTRY","IRL","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"10.6",10.64,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2270928,"AMR_INFECT_ECOLI","COUNTRY","OMN","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"52.3",52.28,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4316190,"AMR_INFECT_ECOLI","UNREGION","202",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"39.7",39.74,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6381260,"AMR_INFECT_ECOLI","COUNTRY","AUT","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"10.2",10.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6660997,"AMR_INFECT_ECOLI","COUNTRY","SWE","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"7.0",6.99,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1520695,"AMR_INFECT_ECOLI","UNREGION","199",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"47.8",47.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[123047,"AMR_INFECT_ECOLI","COUNTRY","THA","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"37.3",37.26,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[273299,"AMR_INFECT_ECOLI","COUNTRY","LBN","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"46.1",46.15,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3422895,"AMR_INFECT_ECOLI","COUNTRY","CZE","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"13.1",13.09,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[7335827,"AMR_INFECT_ECOLI","COUNTRY","BIH","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"22.7",22.7,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[4424954,"AMR_INFECT_ECOLI","COUNTRY","ARG","AMR","YEAR","Americas",null,2021,null,null,null,null,null,null,null,"19.8",19.76,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1486677,"AMR_INFECT_ECOLI","COUNTRY","KOR","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"37.1",37.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[941793,"AMR_INFECT_ECOLI","COUNTRY","LKA","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"67.7",67.67,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6899959,"AMR_INFECT_ECOLI","COUNTRY","LTU","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"17.5",17.53,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1800068,"AMR_INFECT_ECOLI","COUNTRY","TUN","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"35.9",35.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4009754,"AMR_INFECT_ECOLI","COUNTRY","MKD","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"73.4",73.44,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[2726989,"AMR_INFECT_ECOLI","COUNTRY","QAT","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"42.3",42.28,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6558739,"AMR_INFECT_ECOLI","COUNTRY","IRL","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"9.8",9.81,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[5952842,"AMR_INFECT_ECOLI","UNREGION","39",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"21",21.04,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2802049,"AMR_INFECT_ECOLI","COUNTRY","TUN","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"33.6",33.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3096002,"AMR_INFECT_ECOLI","COUNTRY","ZAF","AFR","YEAR","Africa",null,2019,null,null,null,null,null,null,null,"30.7",30.74,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[3750845,"AMR_INFECT_ECOLI","COUNTRY","NLD","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"6.7",6.69,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3771298,"AMR_INFECT_ECOLI","COUNTRY","CHE","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"11.1",11.09,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[7349734,"AMR_INFECT_ECOLI","COUNTRY","IDN","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"71.9",71.88,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2155226,"AMR_INFECT_ECOLI","COUNTRY","MLI","AFR","YEAR","Africa",null,2019,null,null,null,null,null,null,null,"39.7",39.74,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4159905,"AMR_INFECT_ECOLI","COUNTRY","RUS","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"73.2",73.17,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[253167,"AMR_INFECT_ECOLI","COUNTRY","XKX",null,"YEAR",null,null,2021,null,null,null,null,null,null,null,"60.0",60.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2502353,"AMR_INFECT_ECOLI","COUNTRY","MYS","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"27.1",27.13,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5782329,"AMR_INFECT_ECOLI","COUNTRY","SWE","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"7.4",7.36,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[1357501,"AMR_INFECT_ECOLI","COUNTRY","KOR","WPR","YEAR","Western Pacific",null,2016,null,null,null,null,null,null,null,"35.3",35.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[1663844,"AMR_INFECT_ECOLI","COUNTRY","JPN","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"20.7",20.66,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1139262,"AMR_INFECT_ECOLI","COUNTRY","PAK","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"69.2",69.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[928501,"AMR_INFECT_ECOLI","COUNTRY","FIN","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"7.6",7.59,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5175240,"AMR_INFECT_ECOLI","COUNTRY","NPL","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"73",72.97,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1473452,"AMR_INFECT_ECOLI","COUNTRY","CYP","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"30.8",30.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[723803,"AMR_INFECT_ECOLI","COUNTRY","DEU","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"12.2",12.18,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1378213,"AMR_INFECT_ECOLI","COUNTRY","NOR","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"5.3",5.33,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1521349,"AMR_INFECT_ECOLI","COUNTRY","FIN","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"7.8",7.79,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5229920,"AMR_INFECT_ECOLI","UNREGION","518",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"37.1",37.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5721034,"AMR_INFECT_ECOLI","COUNTRY","PSE","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"44.2",44.22,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[771637,"AMR_INFECT_ECOLI","COUNTRY","TUN","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"36.1",36.11,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[110102,"AMR_INFECT_ECOLI","UNREGION","15",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"58.3",58.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[826326,"AMR_INFECT_ECOLI","COUNTRY","MKD","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"79.2",79.25,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3785337,"AMR_INFECT_ECOLI","COUNTRY","OMN","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"49.5",49.48,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3587416,"AMR_INFECT_ECOLI","COUNTRY","FRA","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"9.6",9.59,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4357697,"AMR_INFECT_ECOLI","COUNTRY","PHL","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"35.6",35.62,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1691345,"AMR_INFECT_ECOLI","COUNTRY","MOZ","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"31.6",31.58,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[321793,"AMR_INFECT_ECOLI","COUNTRY","IRQ","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"85.5",85.51,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[5121056,"AMR_INFECT_ECOLI","COUNTRY","DEU","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"10.2",10.2,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2461938,"AMR_INFECT_ECOLI","UNREGION","515",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"44.2",44.22,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5530415,"AMR_INFECT_ECOLI","COUNTRY","ITA","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"28.7",28.66,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6470607,"AMR_INFECT_ECOLI","COUNTRY","UGA","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"88.2",88.24,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2162609,"AMR_INFECT_ECOLI","COUNTRY","RUS","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"66.7",66.67,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1834990,"AMR_INFECT_ECOLI","COUNTRY","LAO","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"45.5",45.52,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6069463,"AMR_INFECT_ECOLI","COUNTRY","JPN","WPR","YEAR","Western Pacific",null,2017,null,null,null,null,null,null,null,"19.6",19.62,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[5462361,"AMR_INFECT_ECOLI","COUNTRY","LUX","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"15.7",15.65,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6246527,"AMR_INFECT_ECOLI","UNREGION","722",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"28.7",28.7,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6090045,"AMR_INFECT_ECOLI","COUNTRY","ZAF","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"28.2",28.2,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3573997,"AMR_INFECT_ECOLI","COUNTRY","ZMB","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"88.7",88.71,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7289208,"AMR_INFECT_ECOLI","COUNTRY","NPL","SEAR","YEAR","South-East Asia",null,2021,null,null,null,null,null,null,null,"80.4",80.39,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[717362,"AMR_INFECT_ECOLI","COUNTRY","BIH","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"20.3",20.34,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1999228,"AMR_INFECT_ECOLI","COUNTRY","HRV","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"16.5",16.5,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4262804,"AMR_INFECT_ECOLI","UNREGION","30",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"15.3",15.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[1010975,"AMR_INFECT_ECOLI","COUNTRY","NLD","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"7.2",7.22,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1358124,"AMR_INFECT_ECOLI","COUNTRY","MKD","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"71",71.05,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3628771,"AMR_INFECT_ECOLI","UNREGION","30",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"29",29.02,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5639481,"AMR_INFECT_ECOLI","UNREGION","9",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"13.3",13.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4507709,"AMR_INFECT_ECOLI","COUNTRY","RUS","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"58.5",58.47,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[5209885,"AMR_INFECT_ECOLI","UNREGION","432",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"20.3",20.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1787262,"AMR_INFECT_ECOLI","UNREGION","34",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"76.2",76.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[76329,"AMR_INFECT_ECOLI","UNREGION","513",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"19.6",19.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[6723790,"AMR_INFECT_ECOLI","COUNTRY","KOR","WPR","YEAR","Western Pacific",null,2018,null,null,null,null,null,null,null,"38.6",38.63,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6375632,"AMR_INFECT_ECOLI","COUNTRY","NLD","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"7.3",7.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1556057,"AMR_INFECT_ECOLI","UNREGION","19",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"23.4",23.36,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[7316476,"AMR_INFECT_ECOLI","COUNTRY","SGP","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"25.8",25.83,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3560534,"AMR_INFECT_ECOLI","COUNTRY","SAU","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"57.3",57.26,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6587012,"AMR_INFECT_ECOLI","UNREGION","14",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"40.5",40.54,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2081186,"AMR_INFECT_ECOLI","COUNTRY","GEO","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"47.1",47.06,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4937624,"AMR_INFECT_ECOLI","COUNTRY","MLT","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"16.4",16.37,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2775739,"AMR_INFECT_ECOLI","COUNTRY","LKA","SEAR","YEAR","South-East Asia",null,2021,null,null,null,null,null,null,null,"57.0",57.02,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6145106,"AMR_INFECT_ECOLI","COUNTRY","ZMB","AFR","YEAR","Africa",null,2019,null,null,null,null,null,null,null,"63.4",63.38,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1419918,"AMR_INFECT_ECOLI","COUNTRY","BGD","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"70",70.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1808095,"AMR_INFECT_ECOLI","COUNTRY","CYP","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"41.0",41.03,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2578032,"AMR_INFECT_ECOLI","COUNTRY","BHR","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"50",50.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[636099,"AMR_INFECT_ECOLI","COUNTRY","CHE","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"9.4",9.45,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4815356,"AMR_INFECT_ECOLI","COUNTRY","LVA","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"33.3",33.33,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2571431,"AMR_INFECT_ECOLI","UNREGION","202",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"70.2",70.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[6416583,"AMR_INFECT_ECOLI","COUNTRY","FRA","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"10.4",10.42,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3015216,"AMR_INFECT_ECOLI","COUNTRY","MWI","AFR","YEAR","Africa",null,2016,null,null,null,null,null,null,null,"78.5",78.52,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[7037106,"AMR_INFECT_ECOLI","COUNTRY","POL","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"17.5",17.51,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2816955,"AMR_INFECT_ECOLI","COUNTRY","BTN","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"56.8",56.78,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[567837,"AMR_INFECT_ECOLI","UNREGION","738",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"42.4",42.38,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[7357843,"AMR_INFECT_ECOLI","UNREGION","35",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"39.2",39.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[2632908,"AMR_INFECT_ECOLI","COUNTRY","MMR","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"80.6",80.56,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[929533,"AMR_INFECT_ECOLI","COUNTRY","EGY","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"87.8",87.8,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1249488,"AMR_INFECT_ECOLI","COUNTRY","UGA","AFR","YEAR","Africa",null,2017,null,null,null,null,null,null,null,"46.1",46.15,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[6553299,"AMR_INFECT_ECOLI","COUNTRY","KWT","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"43.7",43.66,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2224672,"AMR_INFECT_ECOLI","COUNTRY","MWI","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"56.5",56.46,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1692218,"AMR_INFECT_ECOLI","COUNTRY","KOR","WPR","YEAR","Western Pacific",null,2017,null,null,null,null,null,null,null,"32.4",32.39,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[29216,"AMR_INFECT_ECOLI","COUNTRY","AUS","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"13.3",13.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2238418,"AMR_INFECT_ECOLI","UNREGION","753",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"32.4",32.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[227144,"AMR_INFECT_ECOLI","COUNTRY","FIN","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"6.3",6.32,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1678647,"AMR_INFECT_ECOLI","COUNTRY","IRN","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"65.5",65.54,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[7289941,"AMR_INFECT_ECOLI","UNREGION","53",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"13.3",13.29,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6423704,"AMR_INFECT_ECOLI","COUNTRY","CIV","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"90",90.0,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3520177,"AMR_INFECT_ECOLI","COUNTRY","MLI","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"60.8",60.81,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6724427,"AMR_INFECT_ECOLI","COUNTRY","CMR","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"70.0",70.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[677267,"AMR_INFECT_ECOLI","UNREGION","513",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"12.5",12.53,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6118212,"AMR_INFECT_ECOLI","UNREGION","151",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"16.4",16.42,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5770103,"AMR_INFECT_ECOLI","COUNTRY","SAU","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"54.8",54.77,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1972700,"AMR_INFECT_ECOLI","COUNTRY","CHE","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"10.4",10.38,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3786469,"AMR_INFECT_ECOLI","COUNTRY","SDN","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"66.7",66.67,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6376329,"AMR_INFECT_ECOLI","COUNTRY","POL","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"16.7",16.68,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[6649208,"AMR_INFECT_ECOLI","COUNTRY","LAO","WPR","YEAR","Western Pacific",null,2017,null,null,null,null,null,null,null,"45.3",45.28,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[1672039,"AMR_INFECT_ECOLI","UNREGION","747",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"54.7",54.68,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5183379,"AMR_INFECT_ECOLI","COUNTRY","BHR","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"43.2",43.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3895705,"AMR_INFECT_ECOLI","COUNTRY","GEO","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"43.7",43.65,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4256878,"AMR_INFECT_ECOLI","COUNTRY","MWI","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"60.0",60.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6036296,"AMR_INFECT_ECOLI","COUNTRY","OMN","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"54.7",54.68,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5879564,"AMR_INFECT_ECOLI","UNREGION","150",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"14.2",14.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[500303,"AMR_INFECT_ECOLI","COUNTRY","LTU","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"15.3",15.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4086562,"AMR_INFECT_ECOLI","COUNTRY","THA","SEAR","YEAR","South-East Asia",null,2021,null,null,null,null,null,null,null,"37.4",37.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[6043253,"AMR_INFECT_ECOLI","COUNTRY","GRC","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"19.3",19.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6315498,"AMR_INFECT_ECOLI","COUNTRY","LAO","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"50",50.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6752024,"AMR_INFECT_ECOLI","COUNTRY","IRN","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"69.2",69.23,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5572440,"AMR_INFECT_ECOLI","UNREGION","145",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"52.3",52.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5886489,"AMR_INFECT_ECOLI","COUNTRY","KOR","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"36.6",36.63,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[875559,"AMR_INFECT_ECOLI","COUNTRY","IND","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"78.8",78.83,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2456424,"AMR_INFECT_ECOLI","COUNTRY","LTU","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"16.3",16.35,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2286778,"AMR_INFECT_ECOLI","COUNTRY","SWE","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"8.3",8.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2633464,"AMR_INFECT_ECOLI","COUNTRY","KEN","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"78.1",78.05,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4570349,"AMR_INFECT_ECOLI","COUNTRY","UKR","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"60.0",60.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3370650,"AMR_INFECT_ECOLI","COUNTRY","BFA","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"63.6",63.64,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4789200,"AMR_INFECT_ECOLI","COUNTRY","MMR","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"84.9",84.91,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6970100,"AMR_INFECT_ECOLI","COUNTRY","MYS","WPR","YEAR","Western Pacific",null,2018,null,null,null,null,null,null,null,"27.8",27.79,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2416022,"AMR_INFECT_ECOLI","COUNTRY","ETH","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"65",65.0,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4433981,"AMR_INFECT_ECOLI","COUNTRY","COD","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"69.0",68.97,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4897989,"AMR_INFECT_ECOLI","COUNTRY","IDN","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"75.6",75.63,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5832002,"AMR_INFECT_ECOLI","COUNTRY","FIN","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"6.7",6.66,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[1079890,"AMR_INFECT_ECOLI","COUNTRY","LVA","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"20.4",20.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3145803,"AMR_INFECT_ECOLI","COUNTRY","GHA","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"64.3",64.29,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6629223,"AMR_INFECT_ECOLI","UNREGION","419",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"23.4",23.36,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4563672,"AMR_INFECT_ECOLI","COUNTRY","PSE","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"46.2",46.23,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7222355,"AMR_INFECT_ECOLI","COUNTRY","FRA","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"10.2",10.22,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[7290682,"AMR_INFECT_ECOLI","COUNTRY","GRC","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"21.9",21.93,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4332127,"AMR_INFECT_ECOLI","COUNTRY","LKA","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"61.9",61.92,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[7004191,"AMR_INFECT_ECOLI","COUNTRY","ZAF","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"27.7",27.7,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4175688,"AMR_INFECT_ECOLI","COUNTRY","CHE","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"9.6",9.56,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1932281,"AMR_INFECT_ECOLI","COUNTRY","JOR","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"60.4",60.42,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3630280,"AMR_INFECT_ECOLI","UNREGION","35",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"46.1",46.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5784472,"AMR_INFECT_ECOLI","UNREGION","34",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"65.3",65.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[7358796,"AMR_INFECT_ECOLI","COUNTRY","MLT","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"15.9",15.89,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4243895,"AMR_INFECT_ECOLI","COUNTRY","BHR","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"53.8",53.81,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6472345,"AMR_INFECT_ECOLI","UNREGION","747",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"37",37.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[1659736,"AMR_INFECT_ECOLI","COUNTRY","IRL","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"12",11.98,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[5579822,"AMR_INFECT_ECOLI","UNREGION","419",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"17.1",17.1,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1318594,"AMR_INFECT_ECOLI","COUNTRY","GEO","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"35.4",35.37,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[678143,"AMR_INFECT_ECOLI","COUNTRY","NOR","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"5.9",5.87,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[7236225,"AMR_INFECT_ECOLI","COUNTRY","GRC","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"18.3",18.3,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[3951076,"AMR_INFECT_ECOLI","COUNTRY","KOR","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"37.7",37.66,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1223177,"AMR_INFECT_ECOLI","COUNTRY","MWI","AFR","YEAR","Africa",null,2017,null,null,null,null,null,null,null,"71.9",71.91,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4332378,"AMR_INFECT_ECOLI","UNREGION","150",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"11.6",11.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[630568,"AMR_INFECT_ECOLI","COUNTRY","SGP","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"28.7",28.69,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2246393,"AMR_INFECT_ECOLI","COUNTRY","TTO","AMR","YEAR","Americas",null,2020,null,null,null,null,null,null,null,"26.3",26.32,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[719163,"AMR_INFECT_ECOLI","COUNTRY","LBY","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"58.3",58.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[801089,"AMR_INFECT_ECOLI","UNREGION","419",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"20",20.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4441347,"AMR_INFECT_ECOLI","COUNTRY","LAO","WPR","YEAR","Western Pacific",null,2018,null,null,null,null,null,null,null,"45.5",45.45,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3568989,"AMR_INFECT_ECOLI","GLOBAL","GLOBAL",null,"YEAR",null,null,2021,null,null,null,null,null,null,null,"41.0",41.0,null,null,null,"2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[2301171,"AMR_INFECT_ECOLI","COUNTRY","HRV","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"18.2",18.18,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[807968,"AMR_INFECT_ECOLI","COUNTRY","MDV","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"63",62.96,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6902669,"AMR_INFECT_ECOLI","COUNTRY","IDN","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"70.1",70.14,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4400659,"AMR_INFECT_ECOLI","UNREGION","513",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"37.9",37.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1100712,"AMR_INFECT_ECOLI","COUNTRY","CYP","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"37.1",37.1,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[971888,"AMR_INFECT_ECOLI","COUNTRY","ETH","AFR","YEAR","Africa",null,2018,null,null,null,null,null,null,null,"100",100.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3119155,"AMR_INFECT_ECOLI","COUNTRY","JPN","WPR","YEAR","Western Pacific",null,2018,null,null,null,null,null,null,null,"20.1",20.12,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2955159,"AMR_INFECT_ECOLI","COUNTRY","AUT","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"9.6",9.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[1646434,"AMR_INFECT_ECOLI","COUNTRY","MAR","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"35.9",35.87,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7052226,"AMR_INFECT_ECOLI","UNREGION","62",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"62.6",62.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[5382727,"AMR_INFECT_ECOLI","UNREGION","432",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"73.4",73.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[358189,"AMR_INFECT_ECOLI","COUNTRY","LUX","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"11.3",11.34,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4946191,"AMR_INFECT_ECOLI","COUNTRY","ARE","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"46.1",46.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5450808,"AMR_INFECT_ECOLI","COUNTRY","BRA","AMR","YEAR","Americas",null,2021,null,null,null,null,null,null,null,"25.6",25.58,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[583055,"AMR_INFECT_ECOLI","COUNTRY","EGY","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"89.6",89.58,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[7216151,"AMR_INFECT_ECOLI","COUNTRY","MLI","AFR","YEAR","Africa",null,2018,null,null,null,null,null,null,null,"32",32.05,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4005801,"AMR_INFECT_ECOLI","COUNTRY","BIH","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"23.5",23.46,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3085097,"AMR_INFECT_ECOLI","COUNTRY","SWE","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"7.7",7.68,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[610464,"AMR_INFECT_ECOLI","COUNTRY","LVA","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"18",18.02,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[2695976,"AMR_INFECT_ECOLI","COUNTRY","PHL","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"39.9",39.93,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2818577,"AMR_INFECT_ECOLI","COUNTRY","KHM","WPR","YEAR","Western Pacific",null,2020,null,null,null,null,null,null,null,"73.7",73.72,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1830452,"AMR_INFECT_ECOLI","COUNTRY","IDN","SEAR","YEAR","South-East Asia",null,2021,null,null,null,null,null,null,null,"71.1",71.1,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[7264058,"AMR_INFECT_ECOLI","COUNTRY","MLT","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"13.0",13.04,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[576379,"AMR_INFECT_ECOLI","COUNTRY","JPN","WPR","YEAR","Western Pacific",null,2021,null,null,null,null,null,null,null,"20.6",20.64,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1312321,"AMR_INFECT_ECOLI","COUNTRY","ITA","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"28.7",28.7,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[4183310,"AMR_INFECT_ECOLI","COUNTRY","IRQ","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"94.9",94.87,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5764677,"AMR_INFECT_ECOLI","COUNTRY","LBN","EMR","YEAR","Eastern Mediterranean",null,2016,null,null,null,null,null,null,null,"48.5",48.53,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[6554939,"AMR_INFECT_ECOLI","COUNTRY","CHE","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"10.3",10.27,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6780529,"AMR_INFECT_ECOLI","COUNTRY","IRN","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"70.3",70.32,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6650632,"AMR_INFECT_ECOLI","COUNTRY","BIH","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"28.9",28.86,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3897126,"AMR_INFECT_ECOLI","GLOBAL","GLOBAL",null,"YEAR",null,null,2018,null,null,null,null,null,null,null,"36.0",36.0,null,null,null,"2024-03-13T11:45:36.56+01:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3876681,"AMR_INFECT_ECOLI","COUNTRY","TUN","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"31.1",31.08,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2423457,"AMR_INFECT_ECOLI","COUNTRY","NGA","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"80.8",80.77,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[3296634,"AMR_INFECT_ECOLI","UNREGION","15",null,"YEAR",null,null,2016,null,null,null,null,null,null,null,"25.5",25.5,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[1606200,"AMR_INFECT_ECOLI","COUNTRY","BEL","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"10.3",10.33,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2634702,"AMR_INFECT_ECOLI","COUNTRY","NPL","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"77.3",77.27,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6357502,"AMR_INFECT_ECOLI","COUNTRY","PSE","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"47.4",47.37,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4960299,"AMR_INFECT_ECOLI","COUNTRY","MKD","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"85.7",85.71,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6099360,"AMR_INFECT_ECOLI","UNREGION","5",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"23.4",23.36,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6371143,"AMR_INFECT_ECOLI","COUNTRY","MMR","SEAR","YEAR","South-East Asia",null,2019,null,null,null,null,null,null,null,"77.8",77.78,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1462954,"AMR_INFECT_ECOLI","COUNTRY","JOR","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"66.7",66.67,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[112912,"AMR_INFECT_ECOLI","COUNTRY","BIH","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"24.9",24.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[713129,"AMR_INFECT_ECOLI","COUNTRY","CZE","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"14.2",14.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[836101,"AMR_INFECT_ECOLI","COUNTRY","BIH","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"20.2",20.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[999857,"AMR_INFECT_ECOLI","COUNTRY","SAU","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"58.3",58.27,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[4905896,"AMR_INFECT_ECOLI","GLOBAL","GLOBAL",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"36.6",36.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-11-04T12:05:21+01:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[1653858,"AMR_INFECT_ECOLI","COUNTRY","MYS","WPR","YEAR","Western Pacific",null,2017,null,null,null,null,null,null,null,"27.4",27.37,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[5478754,"AMR_INFECT_ECOLI","COUNTRY","NGA","AFR","YEAR","Africa",null,2018,null,null,null,null,null,null,null,"81.6",81.63,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5526315,"AMR_INFECT_ECOLI","COUNTRY","CHE","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"9.2",9.16,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[4346895,"AMR_INFECT_ECOLI","COUNTRY","EST","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"7.9",7.86,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[5383344,"AMR_INFECT_ECOLI","COUNTRY","ARE","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"54.1",54.08,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6930540,"AMR_INFECT_ECOLI","COUNTRY","JOR","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"61.9",61.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6385043,"AMR_INFECT_ECOLI","COUNTRY","PAK","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"82.3",82.29,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6801471,"AMR_INFECT_ECOLI","COUNTRY","NPL","SEAR","YEAR","South-East Asia",null,2018,null,null,null,null,null,null,null,"65.3",65.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[5881387,"AMR_INFECT_ECOLI","COUNTRY","HRV","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"18.2",18.24,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5969984,"AMR_INFECT_ECOLI","COUNTRY","TUR","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"53.8",53.77,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4660968,"AMR_INFECT_ECOLI","COUNTRY","LBY","EMR","YEAR","Eastern Mediterranean",null,2020,null,null,null,null,null,null,null,"61.5",61.54,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1769503,"AMR_INFECT_ECOLI","COUNTRY","KHM","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"71",71.03,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[5922179,"AMR_INFECT_ECOLI","COUNTRY","SAU","EMR","YEAR","Eastern Mediterranean",null,2017,null,null,null,null,null,null,null,"50.9",50.85,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[386135,"AMR_INFECT_ECOLI","UNREGION","747",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"46.6",46.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[7114463,"AMR_INFECT_ECOLI","COUNTRY","DEU","EUR","YEAR","Europe",null,2016,null,null,null,null,null,null,null,"11.6",11.56,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[3836221,"AMR_INFECT_ECOLI","UNREGION","2",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"40.1",40.14,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6099721,"AMR_INFECT_ECOLI","COUNTRY","ZMB","AFR","YEAR","Africa",null,2016,null,null,null,null,null,null,null,"61.9",61.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2016","2016-01-01T00:00:00+01:00","2016-12-31T00:00:00+01:00"]
[6147666,"AMR_INFECT_ECOLI","COUNTRY","IRL","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"12.5",12.53,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4654276,"AMR_INFECT_ECOLI","COUNTRY","BRA","AMR","YEAR","Americas",null,2018,null,null,null,null,null,null,null,"15.9",15.9,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[2165657,"AMR_INFECT_ECOLI","COUNTRY","PHL","WPR","YEAR","Western Pacific",null,2018,null,null,null,null,null,null,null,"36",36.03,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[474925,"AMR_INFECT_ECOLI","COUNTRY","EGY","EMR","YEAR","Eastern Mediterranean",null,2018,null,null,null,null,null,null,null,"97.9",97.87,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[740742,"AMR_INFECT_ECOLI","COUNTRY","MLT","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"11.9",11.91,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[6331090,"AMR_INFECT_ECOLI","COUNTRY","LBN","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"55.3",55.33,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[6760737,"AMR_INFECT_ECOLI","COUNTRY","PAK","EMR","YEAR","Eastern Mediterranean",null,2019,null,null,null,null,null,null,null,"88.9",88.87,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[3740818,"AMR_INFECT_ECOLI","COUNTRY","MUS","AFR","YEAR","Africa",null,2020,null,null,null,null,null,null,null,"49.6",49.59,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[1027604,"AMR_INFECT_ECOLI","COUNTRY","FIN","EUR","YEAR","Europe",null,2020,null,null,null,null,null,null,null,"6.6",6.62,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:49+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[2029479,"AMR_INFECT_ECOLI","UNREGION","746",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"39.9",39.93,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[2976719,"AMR_INFECT_ECOLI","COUNTRY","ARG","AMR","YEAR","Americas",null,2018,null,null,null,null,null,null,null,"20",20.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[3549706,"AMR_INFECT_ECOLI","UNREGION","30",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"26",26.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[4381275,"AMR_INFECT_ECOLI","COUNTRY","MKD","EUR","YEAR","Europe",null,2021,null,null,null,null,null,null,null,"51.2",51.22,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1068654,"AMR_INFECT_ECOLI","GLOBAL","GLOBAL",null,"YEAR",null,null,2017,null,null,null,null,null,null,null,"32.4",32.4,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-11-04T12:05:21+01:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[2465220,"AMR_INFECT_ECOLI","COUNTRY","CZE","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"15.2",15.2,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:21+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[6624074,"AMR_INFECT_ECOLI","COUNTRY","PER","AMR","YEAR","Americas",null,2021,null,null,null,null,null,null,null,"58.7",58.73,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[3174397,"AMR_INFECT_ECOLI","COUNTRY","TLS","SEAR","YEAR","South-East Asia",null,2020,null,null,null,null,null,null,null,"61.5",61.54,null,null,"Proportions are only shown for countries, territories and areas reporting >= 10 bacteriologically confirmed bloodstream infections with antimicrobial susceptibility test results. Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2023-06-06T15:11:50+02:00","2020","2020-01-01T00:00:00+01:00","2020-12-31T00:00:00+01:00"]
[5881759,"AMR_INFECT_ECOLI","COUNTRY","ETH","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"86.2",86.21,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[4510824,"AMR_INFECT_ECOLI","COUNTRY","GBR","EUR","YEAR","Europe",null,2019,null,null,null,null,null,null,null,"11.3",11.27,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4954168,"AMR_INFECT_ECOLI","COUNTRY","LBN","EMR","YEAR","Eastern Mediterranean",null,2021,null,null,null,null,null,null,null,"50.0",50.0,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[311625,"AMR_INFECT_ECOLI","COUNTRY","JPN","WPR","YEAR","Western Pacific",null,2019,null,null,null,null,null,null,null,"21",20.95,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:23+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]
[4449384,"AMR_INFECT_ECOLI","COUNTRY","BFA","AFR","YEAR","Africa",null,2021,null,null,null,null,null,null,null,"80.8",80.77,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2024-03-13T11:45:36.56+01:00","2021","2021-01-01T00:00:00+01:00","2021-12-31T00:00:00+01:00"]
[1545458,"AMR_INFECT_ECOLI","COUNTRY","LTU","EUR","YEAR","Europe",null,2017,null,null,null,null,null,null,null,"12.5",12.5,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:20+02:00","2017","2017-01-01T00:00:00+01:00","2017-12-31T00:00:00+01:00"]
[7176418,"AMR_INFECT_ECOLI","COUNTRY","POL","EUR","YEAR","Europe",null,2018,null,null,null,null,null,null,null,"17.6",17.6,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. AMR Surveillance National Coordinating Center","2022-05-09T11:15:22+02:00","2018","2018-01-01T00:00:00+01:00","2018-12-31T00:00:00+01:00"]
[1968257,"AMR_INFECT_ECOLI","UNREGION","485",null,"YEAR",null,null,2019,null,null,null,null,null,null,null,"46.1",46.08,null,null,"Percentage of bloodstream infection due to  Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested. Global Antimicrobial Resistance Surveillance System (GLASS). Geneva: WHO, 2020.","2022-05-09T11:15:22+02:00","2019","2019-01-01T00:00:00+01:00","2019-12-31T00:00:00+01:00"]